Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental procedure; and Remplir, a collagen scaffold used in peripheral nerve repair. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $0.7384281761758769 | N/A |
Market Cap | $145.63M | N/A |
Shares Outstanding | 197.21M | 1.31% |
Employees | 0 | N/A |
Shareholder Equity | 6.15M | -37.92% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -23.08 | N/A |
P/S Ratio | 55.08 | N/A |
P/B Ratio | 23.68 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.6332 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $2.64M | N/A |
Earnings | -$3.89M | N/A |
EPS | -0.032 | N/A |
Earnings Yield | -0.0433 | N/A |
Gross Margin | 0.7582 | N/A |
Operating Margin | -2.57 | N/A |
Net income margin | -1.47 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $18.45M | N/A |
Total Debt | $350.40K | N/A |
Cash on Hand | $15.47M | N/A |
Debt to Equity | $2.38 | 34.98% |
Cash to Debt | $44.14 | 103.26% |
Current Ratio | $5.93 | 14.65% |